全文获取类型
收费全文 | 21518篇 |
免费 | 1927篇 |
国内免费 | 50篇 |
专业分类
耳鼻咽喉 | 187篇 |
儿科学 | 694篇 |
妇产科学 | 542篇 |
基础医学 | 3074篇 |
口腔科学 | 240篇 |
临床医学 | 2500篇 |
内科学 | 4218篇 |
皮肤病学 | 299篇 |
神经病学 | 2424篇 |
特种医学 | 489篇 |
外国民族医学 | 1篇 |
外科学 | 2234篇 |
综合类 | 270篇 |
一般理论 | 19篇 |
预防医学 | 3088篇 |
眼科学 | 292篇 |
药学 | 1329篇 |
中国医学 | 29篇 |
肿瘤学 | 1566篇 |
出版年
2024年 | 42篇 |
2023年 | 364篇 |
2022年 | 589篇 |
2021年 | 1222篇 |
2020年 | 752篇 |
2019年 | 1032篇 |
2018年 | 1101篇 |
2017年 | 738篇 |
2016年 | 752篇 |
2015年 | 827篇 |
2014年 | 1031篇 |
2013年 | 1326篇 |
2012年 | 1933篇 |
2011年 | 1891篇 |
2010年 | 872篇 |
2009年 | 749篇 |
2008年 | 1223篇 |
2007年 | 1101篇 |
2006年 | 951篇 |
2005年 | 779篇 |
2004年 | 667篇 |
2003年 | 593篇 |
2002年 | 465篇 |
2001年 | 190篇 |
2000年 | 187篇 |
1999年 | 180篇 |
1998年 | 126篇 |
1997年 | 112篇 |
1996年 | 89篇 |
1995年 | 93篇 |
1994年 | 66篇 |
1993年 | 71篇 |
1992年 | 120篇 |
1991年 | 99篇 |
1990年 | 89篇 |
1989年 | 73篇 |
1988年 | 66篇 |
1987年 | 57篇 |
1986年 | 62篇 |
1985年 | 67篇 |
1984年 | 61篇 |
1983年 | 46篇 |
1981年 | 32篇 |
1979年 | 47篇 |
1978年 | 35篇 |
1976年 | 39篇 |
1975年 | 40篇 |
1974年 | 44篇 |
1972年 | 34篇 |
1971年 | 32篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
201.
202.
Cross P 《Health services management》1990,86(6):284-286
Investment in information technology by the NHS is reaching unprecedented levels. This is true throughout the service, from the highly publicized district information systems and hospital information support systems to the investment of GPs in microcomputers. To place all these system developments in context, Peter Cross considers the changes in the structure of health computing in the 1980s and sets out a methodology for assessing both the need for computer systems and their success. 相似文献
203.
204.
Wen Chen Jessica M. Gullett Rebecca E. Tweedell Thirumala-Devi Kanneganti 《European journal of immunology》2023,53(11):2250235
Regulated cell death (RCD) triggered by innate immune activation is an important strategy for host survival during pathogen invasion and perturbations of cellular homeostasis. There are two main categories of RCD, including nonlytic and lytic pathways. Apoptosis is the most well-characterized nonlytic RCD, and the inflammatory pyroptosis and necroptosis pathways are among the best known lytic forms. While these were historically viewed as independent RCD pathways, extensive evidence of cross-talk among their molecular components created a knowledge gap in our mechanistic understanding of RCD and innate immune pathway components, which led to the identification of PANoptosis. PANoptosis is a unique innate immune inflammatory RCD pathway that is regulated by PANoptosome complexes upon sensing pathogens, pathogen-associated molecular patterns (PAMPs), damage-associated molecular patterns (DAMPs) or the cytokines produced downstream. Cytosolic innate immune sensors and regulators, such as ZBP1, AIM2 and RIPK1, promote the assembly of PANoptosomes to drive PANoptosis. In this review, we discuss the molecular components of the known PANoptosomes and highlight the mechanisms of PANoptosome assembly, activation and regulation identified to date. We also discuss how PANoptosomes and mutations in PANoptosome components are linked to diseases. Given the impact of RCD, and PANoptosis specifically, across the disease spectrum, improved understanding of PANoptosomes and their regulation will be critical for identifying new therapeutic targets and strategies. 相似文献
205.
Valentina Mazzotta Alessandro Cozzi Lepri Francesca Colavita Silvia Rosati Eleonora Lalle Claudia Cimaglia Jessica Paulicelli Ilaria Mastrorosa Serena Vita Lavinia Fabeni Alessandra Vergori Gaetano Maffongelli Fabrizio Carletti Simone Lanini Emanuela Caraffa Eugenia Milozzi Raffaella Libertone Pierluca Piselli Enrico Girardi AnnaRosa Garbuglia Francesco Vaia Fabrizio Maggi Emanuele Nicastri Andrea Antinori INMI COVID- Outpatient Treatment Study Group 《Journal of medical virology》2023,95(1):e28186
206.
Shun Kaneko Masayuki Kurosaki Toshie Mashiba Hiroyuki Marusawa Masahiko Kondo Yuji Kojima Yasushi Uchida Hideki Fujii Takehiro Akahane Hitoshi Yagisawa Atsunori Kusakabe Haruhiko Kobashi Takehiko Abe Hideo Yoshida Chikara Ogawa Koichiro Furuta Nobuharu Tamaki Keiji Tsuji Tomomichi Matsushita Namiki Izumi the Japanese Red Cross Liver Study Group 《Journal of medical virology》2023,95(1):e28210
Nucleos(t)ide analogs (NAs) cannot completely suppress the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). This study aimed to identify the risk factors for HCC development in naïve CHB patients treated with current NA. Patients receiving NA (n = 905) were recruited retrospectively from the 17 hospitals of the Japanese Red Cross Liver Study Group. All treatment-naïve patients had been receiving current NA continuously for more than 1 year until the end of the follow-up. We analyzed the accuracy of predictive risk score using the area under receiver operating characteristic curve. The albumin–bilirubin (ALBI) score was significantly improved by NA therapy (−0.171 ± 0.396; p < 0.001 at Week 48). A total of 72 (8.0%) patients developed HCC over a median follow-up of 6.2 (1.03–15.7) years. An independent predictive factor of HCC development was older age, cirrhosis, lower platelet counts at baseline and ALBI score, and alpha-fetoprotein (AFP) at 1 year after NA therapy according to multivariate analysis. The accuracy was assessed using the PAGE-B, mPAGE-B, aMAP, APA-B, and REAL-B scores that included these factors. Discrimination was generally acceptable for these models. aMAP and REAL-B demonstrated high discrimination with 0.866/0.862 and 0.833/0.859 for 3- and 5-year prediction from the status of 1 year after NA therapy, respectively. Baseline age and platelet count, as well as ALBI and AFP one year after NA, were useful for stratifying carcinogenesis risk. The aMAP and REAL-B scores were validated with high accuracy in Japanese CHB patients. 相似文献
207.
Lisanne E. de Koning Jessica Warnink-Kavelaars Marion A. van Rossum Diederik Bosman Leonie A. Menke Fransiska Malfait Rosa de Boer Jaap Oosterlaan Raoul H. H. Engelbert Lies Rombaut And the Pediatric Heritable Connective Tissue Disorders Study Group 《American journal of medical genetics. Part A》2023,191(7):1792-1803
The aim of the present study was to investigate the nature and prevalence of nonspecific somatic symptoms, pain and catastrophizing in children with Heritable Connective Tissue Disorders (HCTD), and to determine their association with disability. This observational, multicenter study included 127 children, aged 4–18 years, with Marfan syndrome (MFS) (59%), Loeys-Dietz syndrome (LDS) (8%), Ehlers-Danlos syndromes (EDS) (12%) and hypermobile Ehlers-Danlos syndrome (hEDS) (23%). The assessments included the Children's Somatization Inventory or parent proxy (CSI, PCSI), pain visual-analogue scale (VAS), SUPERKIDZ body diagram, Pain Catastrophizing Scale Child or parent proxy (PCS-C, PCS-P) and Childhood Health Assessment Questionnaire (CHAQ-30). Data from children aged ≥8 years were compared to normative data. In children ≥ 8 years (n = 90), pain was present in 59%, with a median of 4 (IQR = 3–9) pain areas. Compared to normative data, the HCTD group reported significantly higher on the CSI (p ≤ 0.001, d = 0.85), VAS pain intensity (p ≤ 0.001, d = 1.22) and CHAQ-30 (p ≤ 0.001, d = 1.16) and lower on the PCS-C (p = 0.017, d = −0.82) and PCS-P (p ≤ 0.001, d = −0.49). The intensity of nonspecific somatic symptoms and pain explained 45% of the variance in disability (r2 = 0.45 F(2,48) = 19.70, p ≤ 0.001). In children ≤ 7 years (n = 37), pain was present in 35% with a median of 5(IQR = 1–13) pain areas. The mean(SD) VAS scores for pain intensity was 1.5(2.9). Functional disability was moderately correlated to the number of pain areas (r = 0.56, p ≤ 0.001), intensity of nonspecific somatic symptoms (r = 0.63, p ≤ 0.001) and pain (r = 0.83, p ≤ 0.001). In conclusion, this study supports the need for comprehensive assessment of nonspecific somatic symptoms, pain, and disability in children with HCTD to allow tailored treatment. 相似文献
208.
209.
Cross M 《The Health service journal》1997,107(5572):suppl 11-suppl 12
210.
Cross M 《The Health service journal》1997,107(5538):suppl 7-suppl 8